Prosecution Insights
Last updated: April 19, 2026

Angiocrine Bioscience, Inc.

2 pending office actions

Portfolio Summary

2
Total Pending OAs
1
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18003124 ENDOTHELIAL CELLS FOR MITIGATION OF CHEMOTHERAPY-INDUCED TOXICITY SCHUBERG, LAURA J 1631 Non-Final OA Dec 22, 2022
17614521 COMPOSITIONS AND METHODS FOR THYMIC REGENERATION AND T-CELL RECONSTITUTION JOHNSON, ALLISON MARIE 1638 Final Rejection Nov 27, 2021

Managing Angiocrine Bioscience, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month